Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03451799 · ClinicalTrials.gov registry record · Phase 1
Ketogenic Diet in Combination With Standard-of-care Radiation and Temozolomide for Patients With Glioblastoma
A Phase 1 study of Glioblastoma and GBM, sponsored by Jethro Hu.
- Active
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT03451799: Active Phase 1 study of Glioblastoma and GBM, sponsored by Jethro Hu.
NCT03451799 is a Phase 1 study of Glioblastoma and GBM that is active but no longer recruiting, run by Jethro Hu. The registered enrollment target is 21 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03451799, a Phase 1 study of Glioblastoma and GBM, is active but no longer recruiting, sponsored by Jethro Hu.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
Enrolled subjects will be placed on a 16-week ketogenic diet (subject specific as prescribed by RD) while receiving standard of care cancer treatment (Radiation + Temozolomide). Study dietitians will create personalized meal plans for each patient with the goal of achieving and maintaining protocol defined metabolic ketosis. Subjects will be monitored for safety, nutrition, quality of life, and standard of care tumor assessments over the course of the study.
Primary Outcome
Proportion of participants experiencing a 10% decrease in weight or body mass index AND have a BMI \<18.5 within one month from initiation of the ketogenic diet.
Conditions Studied
Interventions
- OTHER Ketogenic Diet
- RADIATION Standard-of-care radiation
- DRUG Standard-of-care Temozolomide
Study Locations (1)
California
- Cedars Sinai Medical Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2018-04-13 |
| Est. Completion | 2026-05 |
| Phase | Phase 1 |
What the registry record for NCT03451799 still lists
NCT03451799 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (81% lower).
The record links to 2 conditions, with Glioblastoma appearing as the primary indexed condition, and to 3 interventions - of which Ketogenic Diet is the first listed.
NCT03451799 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03451799 about?
NCT03451799 is a clinical study titled "Ketogenic Diet in Combination With Standard-of-care Radiation and Temozolomide for Patients With Glioblastoma". Enrolled subjects will be placed on a 16-week ketogenic diet (subject specific as prescribed by RD) while receiving standard of care cancer treatment (Radiation + Temozolomide). Study dietitians will create personalized meal plans for each patient with the goal of achieving and maintaining protocol ...
What is the current status of trial NCT03451799?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2018-04-13. Estimated completion is 2026-05.
What conditions does trial NCT03451799 study?
This clinical trial studies the following conditions: Glioblastoma, GBM.
What interventions are being tested in trial NCT03451799?
The interventions under investigation include: Ketogenic Diet (OTHER), Standard-of-care radiation (RADIATION), Standard-of-care Temozolomide (DRUG).
Who is sponsoring clinical trial NCT03451799?
This trial is sponsored by Jethro Hu, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03451799 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03451799's enrollment target sits among peer trials
21 145th of 199 higher than 53 of 199 other Glioblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
-
A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
RECRUITING · Phase 1
-
CARv3-TEAM-E T Cells in Glioblastoma
RECRUITING · Phase 1
-
CUE-102 in Recurrent Glioblastoma
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI